Table 1 Key oncological biologics whose patents either have expired or will expire soon
From: What do oncologists need to know about biosimilar products?
Biologic (brand name) | Manufacturer | Estimated patent expiry (month and year) | |
|---|---|---|---|
United States | Europe | ||
Supportive agents | |||
Filgrastim (Neupogen) | Amgen/Roche/Jassen | Expired | Expired |
Pegfilgrastim (Neulasta) | Amgen | Expired | Aug 2017 |
Epoetin alfa (Emprex/Epogen/Procrit) | Amgen/Jassen | Expired | Expired |
Darbepoetin alfa (Aranesp) | Amgen | May 2024 | Jul 2016 |
Monoclonal antibodies | |||
Trastuzumab (Herceptin) | Genentech/Roche | Jun 2019 | Expired |
Rituximab (Rituxan/MabThera) | Roche | Sep 2016 | Expired |
Cetuximab (Erbitux) | Eli Lilly/Bristol-Myers Squibb/Merck KgaA | Expired | Expired |
Bevacizumab (Avastin) | Genentech/Roche | Jul 2019 | Jan 2022 |